Cellceutix Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy’s Laboratories For Manufacturing
August 30, 2012 | Press Releases
Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials
August 6, 2012 | Press Releases
Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials; Site Initiation Visit for Clinical Trials of Kevetrin to Happen This Week
July 16, 2012 | Press Releases
Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug
July 9, 2012 | Press Releases
Cellceutix Novel Anti-Cancer Drug Kevetrin™ Receives IRB and SRC Approvals for Clinical Trials at Harvard’s Dana-Farber Cancer Institute
June 26, 2012 | Press Releases
Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug
June 22, 2012 | Press Releases
Cellceutix Preparing for Phase 2 Clinical Trials With New Psoriasis Drug
June 18, 2012 | Press Releases
Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoriasis Drug
June 13, 2012 | Press Releases